• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Life Sciences Investor Forum Agenda Announced for March 13th

    3/12/25 1:12:37 PM ET
    $CGTX
    $COCP
    $FBLG
    $PDSB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CGTX alert in real time by email

    NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research.

    Individual investors, institutional investors, advisors, and analysts are invited to attend.

    REGISTER NOW AT:   https://bit.ly/4hnure6

    It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.

    "We look forward to bringing together innovators from the life sciences sector," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "This Virtual Investor Conference co-hosted by Zack's Small Cap Research, will provide an efficient platform for these companies to seamlessly engage and broaden their investor base." 

    March 13th

    Eastern

    Time (ET)
    PresentationTicker(s)
    9:30 AM ETCognition Therapeutics, Inc.(NASDAQ:CGTX)
    10:00 AM ETBiophytis SA(OTC:BPTSY, FP: ALBPS))
    10:30 AM ETAvicanna Inc.(OTCQX:AVCNF, TSX:AVCN)
    11:00 AM ETPsy Therapeutics, Inc.Private
    11:30 AM ETCocrystal Pharma, Inc.(NASDAQ:COCP)
    12:00 PM ETNervGen Pharma Corp.(OTCQB:NGENF, TSXV:NGEN)
    12:30 PM ETFibroBiologics, Inc.(NASDAQ:FBLG)
    1:00 PM ETTelescope Innovations Corp.(OTCQB:TELIF, CSE:TELI)
    1:30 PM ETRafarma Pharmaceuticals, Inc.(OTC:RAFA)
    2:00 PM ETIzotropic Corporation(OTCQB:IZOZF, CSE:IZO)
    2:30 PM ETPDS Biotechnology Corporation(NASDAQ:PDSB)
    3:00 PM ETLadRX Corporation(OTCQB:LADX)
    3:30 PM ETTonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP)
    4:00 PM ETHemostemix, Inc.(OTCQB:HMTXF, TSXV:HEM)



    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $CGTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGTX
    $COCP
    $FBLG
    $PDSB

    CompanyDatePrice TargetRatingAnalyst
    Cognition Therapeutics Inc.
    $CGTX
    12/19/2024$1.00 → $1.50Neutral → Buy
    B. Riley Securities
    FibroBiologics Inc.
    $FBLG
    12/12/2024$12.00Buy
    Rodman & Renshaw
    FibroBiologics Inc.
    $FBLG
    10/30/2024$12.00Buy
    H.C. Wainwright
    FibroBiologics Inc.
    $FBLG
    9/24/2024$12.00Buy
    Maxim Group
    Cognition Therapeutics Inc.
    $CGTX
    7/30/2024Overweight → Neutral
    Cantor Fitzgerald
    PDS Biotechnology Corporation
    $PDSB
    11/1/2022$10.00Buy
    B. Riley Securities
    Tonix Pharmaceuticals Holding Corp.
    $TNXP
    4/18/2022Outperform
    Noble Capital Markets
    Cognition Therapeutics Inc.
    $CGTX
    11/3/2021$27.00Buy
    B. Riley Securities
    More analyst ratings

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & President Ricciardi Lisa covered exercise/tax liability with 5,850 shares, decreasing direct ownership by 0.34% to 1,706,676 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    2/18/26 4:17:18 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Doyle John Brendan covered exercise/tax liability with 1,560 shares, decreasing direct ownership by 0.25% to 617,509 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    2/18/26 4:16:26 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Caggiano Anthony covered exercise/tax liability with 4,680 shares, decreasing direct ownership by 0.54% to 864,906 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    2/18/26 4:15:23 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

    CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory University School of MedicineNo approved antiviral therapies or vaccines for norovirus infections demonstrate an immediate market need BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") announces that initial progress of a norovirus challenge study with its direct-acting, oral protease inhibitor CDI-988 will be presented at the 39th International Conference on Antiviral Research (ICAR2026), being held April 27–May 1 

    2/19/26 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University

    HOUSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chairman and CEO Pete O'Heeron has been invited to serve as a main stage speaker at the upcoming A4LI's H-SPAN Summit at Georgetown University. The summit, taking place June 29–July 1, 2026, is hosted by the Alliance for Longevity Initiatives (A4LI) and is recognized as a premier event bringing together leaders, innovators, policymakers, and

    2/10/26 8:30:00 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

    HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 3118732, titled "Treatment of Cachexia Using Fibroblast Cells and Products Thereof." This patent strengthens FibroBiologics' intellectual property portfolio and underscores the Company's commitment to advancing innovative therapies for debilitating conditions like cachexi

    2/5/26 8:30:00 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Frost Phillip Md Et Al bought $47,280 worth of shares (50,000 units at $0.95) (SEC Form 4)

    4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

    2/9/26 4:10:05 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Frost Phillip Md Et Al bought $47,275 worth of shares (50,000 units at $0.95) (SEC Form 4)

    4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

    1/2/26 4:10:19 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Frost Phillip Md Et Al bought $19,310 worth of shares (20,000 units at $0.97) (SEC Form 4)

    4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

    12/31/25 4:10:17 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    SEC Filings

    View All

    Cocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)

    2/19/26 8:30:54 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - FibroBiologics, Inc. (0001958777) (Filer)

    2/6/26 4:10:23 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    2/3/26 7:00:44 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cognition Therapeutics upgraded by B. Riley Securities with a new price target

    B. Riley Securities upgraded Cognition Therapeutics from Neutral to Buy and set a new price target of $1.50 from $1.00 previously

    12/19/24 7:33:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on FibroBiologics with a new price target

    Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

    12/12/24 8:54:24 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on FibroBiologics with a new price target

    H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

    10/30/24 6:37:36 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Leadership Updates

    Live Leadership Updates

    View All

    Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

    CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated commercial-stage biotechnology company today announced the appointment of Irina Ishak as General Counsel, effective December 8, 2025. Ms. Ishak will lead Tonix's legal, corporate governance, and compliance functions. "Irina is a highly accomplished corporate and commercial attorney whose experience spans public and private life sciences companies, as well as advising life sciences investors," said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. "Her deep background in complex transactions, public company matters, and governa

    12/9/25 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

    Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years Cash and cash equivalents of $190.1 million reported as of September 30, 2025; current cash runway expected to fund operations into the first quarter of 2027 CHATHAM, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated commercial biotechnology company today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent operational highlights. "Following U.S. Food a

    11/10/25 4:15:00 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

    Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) (the "Company" or "Cocrystal") announces the completion of a private placement of units priced at-the-market under Nasdaq rules with 743,024 shares of its common stock at a purchase price of $1.39 per unit for proceeds of $1.03 million and unregistered warrants to purchase up to 1,486,048 shares of common stock at an exercise price of $1.24 per share. The warrants are exercisable upon issuance and will expire in 27 months. The four Investors in th

    10/30/25 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Financials

    Live finance-specific insights

    View All

    Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

    PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi will participate in an "unplugged" fireside discussion at the annual Piper Sandler Healthcare Conference. The conference will take place December 2-4, 2025 at The Lotte New York Palace hotel. Details of Cognition's fireside discussion are as follows: Event: 37th Annual Piper Sandler Healthcare Conference   Date/Time: Wednesday, December 3rd at 4:30p.m. Eastern Time Webcast: https://event.webcasts.com/starthere.jsp?ei=1742473&tp_key=11

    11/20/25 4:01:00 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease

    PURCHASE, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company has reached target enrollment of 540 participants in the randomized, placebo-controlled Phase 2 ‘START' Study. A number of additional patients are in the final stages of screening and will be randomized if they meet all eligibility requirements. START will assess the safety and activity of zervimesine (CT1812) in participants with mild cognitive impairment (MCI) or early Alzheimer's disease. Topline results are expected after all participants have completed 18 mo

    11/13/25 7:36:19 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

    Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval Pathway in OngoingVERSATILE-003 Phase 3 Trial Design Conference Call and Webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business update, reported financial results for the third quarter ended September 30, 2025, and provided a clinical program

    11/13/25 7:30:00 AM ET
    $PDSB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:42:22 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:40:17 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    10/16/24 9:01:20 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care